Type a ticker — we pressure-test it against live facts, filings, and sentiment.
Editas Medicine, Inc. — Healthcare · Biotechnology carries a Plainview business-quality score of 4.5/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.
On the fundamentals, Editas Medicine, Inc. shows trailing revenue of $47.0M, net cash of $163.4M, a loss per share of -1.12, valued at about 8.8x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.